Frontiers Case report: Short-term eculizumab use in atypical HUS
Por um escritor misterioso
Descrição
Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era
Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era
PDF) The use of eculizumab in gemcitabine induced thrombotic microangiopathy
Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era
Frontiers Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
atypical hemolytic uremic syndrome - List of Frontiers' open access articles
Frontiers Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report
Spotlight on aHUS Research - July 2021 - aHUS Alliance Action
PDF] Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
Frontiers Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19
Frontiers Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review
PDF) Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease
de
por adulto (o preço varia de acordo com o tamanho do grupo)
